<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597129</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hPAM4-01</org_study_id>
    <nct_id>NCT00597129</nct_id>
    <nct_alias>NCT00303680</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy Study of 90Y-hPAM4 at Different Doses</brief_title>
  <official_title>A Phase I, Dose-Escalating Study to Investigate the Safety, Tolerability, Pharmacokinetics and Dosimetry of a Single Dose of 90YHumanized PAM4 IgG in Patients With Locally Advanced/Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety study to determine highest dose of 90Y-hPAM4 can be safety administered
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      radiolabeled anti-MUC1 humanized antibody) administered intravenously as a single dose to
      patients with locally advanced and/or metastatic pancreatic cancer. The primary objective is
      to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of 90Y-hPAM4
      in this population. Secondary objectives include the assessment of tumor targeting,
      biodistribution, organ dosimetry and pharmacokinetics (PK) of 90Y-hPAM4 as determined by
      pre-therapy administration of 111In-hPAM4, the assessment of the antigenicity of 90Y-hPAM4,
      as determined by development of human anti-humanized antibodies (HAHA), and to obtain
      preliminary information on the efficacy of single dose 90Y-hPAM4 in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety MTD</measure>
    <time_frame>over the first 12 weeks, then over 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>targeting, biodistribution, organ dosimetry</measure>
    <time_frame>first 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics (PK), antigenicity,</measure>
    <time_frame>first 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>over first 12 weeks, then over 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Multi Dose levels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>different doses of 90YhPAM4 will be given only once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>90Y-hPAM4</intervention_name>
    <description>Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.</description>
    <arm_group_label>Multi Dose levels</arm_group_label>
    <other_name>111-IN-hPAM4</other_name>
    <other_name>MUC-1 antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, &gt;18 years of age, who are able to understand and give written
             informed consent.

          -  Histologically or cytologically confirmed, Stage III or IV pancreatic adenocarcinoma.

          -  Patients with Stage III (locally advanced) disease must have documented progression
             after failing primary therapy

          -  Patients with Stage IV (metastatic) disease must not have received more than one
             chemotherapy regimen.

          -  Measurable disease by CT, with at least on lesion &gt;1.5 cm in one dimension.

          -  Karnofsky performance status &gt; 70 % (Appendix A).

          -  Expected survival &gt; three months.

          -  At least 4 weeks beyond chemotherapy, radiotherapy, major surgery, other experimental
             treatments, and recovered from all acute toxicities.

          -  At least 2 weeks beyond corticosteroids, except low doses (i.e., 20 mg/day of
             prednisone or equivalent) to treat nausea or other illness such as rheumatoid
             arthritis

          -  Adequate hematology without ongoing transfusional support (hemoglobin &gt; 10 g/dL, ANC &gt;
             1,500 per mm3, platelets &gt; 150,000 per mm3)

          -  Adequate renal and hepatic function (creatinine and bilirubin ≤ 1.5 X IULN, AST and
             ALT ≤ 2.0 X IULN)

          -  Otherwise, all toxicity at study entry &lt;Grade 1 by NCI CTC v3.0.

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Women of childbearing potential and fertile men unwilling to use effective
             contraception during study until conclusion of 12-week post-treatment evaluation
             period.

          -  Known metastatic disease to the central nervous system.

          -  Presence of bulky disease (defined as any single mass &gt;10 cm in its greatest
             dimension)

          -  Patients with &gt;Grade 2 anorexia, nausea or vomiting, and/or signs of intestinal
             obstruction.

          -  Prior treatment with nitrosureas, actinomycin-D, radioimmunotherapy or other
             antibody-based therapies (murine, chimeric, humanized or human) Prior radiation dose
             &gt;3,000 cGy to the liver, &gt;2,000 cGy to lungs and kidneys or prior external beam
             irradiation to a field that includes more than 30% of the red marrow.

          -  Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not
             excluded, but patients with other prior malignancies must have had at least a 5- year
             disease free interval.

          -  Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.

          -  Known history of active coronary artery disease, unstable angina, myocardial
             infarction, or congestive heart failure present within 6 months or cardiac arrhythmia
             requiring anti-arrhythmia therapy.

          -  Known history of active COPD, or other moderate-to-severe respiratory illness present
             within 6 months.

          -  Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid
             arthritis requiring only low dose maintenance corticosteroids).

          -  Infection requiring intravenous antibiotic use within 1 week.

          -  Other concurrent medical or psychiatric conditions that, in the Investigator's
             opinion, may be likely to confound study interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goshen Cancer Center</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007 Dec 15;13(24):7380-7.</citation>
    <PMID>18094420</PMID>
  </reference>
  <reference>
    <citation>Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther. 2006 Feb;5(2):200-8. Review.</citation>
    <PMID>16505092</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.</citation>
    <PMID>16344318</PMID>
  </reference>
  <reference>
    <citation>Modrak DE, Karacay H, Cardillo TM, Newsome G, Goldenberg DM, Gold DV. Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16). Int J Oncol. 2005 Jun;26(6):1591-6.</citation>
    <PMID>15870874</PMID>
  </reference>
  <reference>
    <citation>Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res. 2004 Nov 15;64(22):8405-10.</citation>
    <PMID>15548711</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004 Apr 20;109(4):618-26.</citation>
    <PMID>14991585</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.</citation>
    <PMID>14506191</PMID>
  </reference>
  <reference>
    <citation>Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biol. 2003 Jan-Feb;24(1):32-9.</citation>
    <PMID>12743424</PMID>
  </reference>
  <reference>
    <citation>Reddy PK, Gold DV, Cardillo TM, Goldenberg DM, Li H, Burton JD. Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction. Eur J Cancer. 2003 Feb;39(3):397-404.</citation>
    <PMID>12565994</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer. 2002 Jan 20;97(3):386-92.</citation>
    <PMID>11774294</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001 Oct;7(10):3186-92.</citation>
    <PMID>11595713</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54.</citation>
    <PMID>11418312</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Cardillo T, Vardi Y, Blumenthal R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int J Cancer. 1997 May 16;71(4):660-7.</citation>
    <PMID>9178823</PMID>
  </reference>
  <reference>
    <citation>Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, Salvadori PA, Giulianotti PC, Mosca F, Gold DV, et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.</citation>
    <PMID>7493369</PMID>
  </reference>
  <reference>
    <citation>Alisauskus R, Wong GY, Gold DV. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5743s-5748s.</citation>
    <PMID>7493339</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res. 1995 Mar 1;55(5):1105-10.</citation>
    <PMID>7866995</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994 Apr 15;57(2):204-10.</citation>
    <PMID>7512537</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>January 8, 2008</last_update_submitted>
  <last_update_submitted_qc>January 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>William Wegener, MD, PHD</name_title>
    <organization>Immunomedics, Inc.</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>cancer of the pancreas</keyword>
  <keyword>pancreas cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

